Global Atherosclerosis Therapeutics Market 2019-2023
SKU ID : TNV-14541052 | Publishing Date : 06-Aug-2019 | No. of pages : 136
Detailed TOC of Global Atherosclerosis Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Small molecules - Market size and forecast 2018-2023
• Biologics - Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Identification of new pathogenic targets
• Identification of new drug targets for atherosclerosis
• Strong incidence of coronary heart disease (CHD)
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• Bayer AG
• Merck & Co. Inc.
• Novartis AG
• Sanofi
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Hypothesis behind LDL deposition in intima
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Some of the key clinical trials in global atherosclerosis therapeutics market
Exhibit 20: Product - Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 24: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Adoption rate of health insurance coverage among US adults with CHD, or a stroke, or both, 2019
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Incidence rate of CHD in adults aged 45 years and above 2019
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca Plc - Vendor overview
Exhibit 53: AstraZeneca Plc - Business segments
Exhibit 54: AstraZeneca Plc - Organizational developments
Exhibit 55: AstraZeneca Plc - Geographic focus
Exhibit 56: AstraZeneca Plc - Key offerings
Exhibit 57: AstraZeneca Plc - Key customers
Exhibit 58: Bayer AG - Vendor overview
Exhibit 59: Bayer AG - Business segments
Exhibit 60: Bayer AG - Organizational developments
Exhibit 61: Bayer AG - Geographic focus
Exhibit 62: Bayer AG - Segment focus
Exhibit 63: Bayer AG - Key offerings
Exhibit 64: Bayer AG - Key customers
Exhibit 65: Merck & Co. Inc. - Vendor overview
Exhibit 66: Merck & Co. Inc. - Business segments
Exhibit 67: Merck & Co. Inc. - Organizational developments
Exhibit 68: Merck & Co. Inc. - Geographic focus
Exhibit 69: Merck & Co. Inc. - Segment focus
Exhibit 70: Merck & Co. Inc. - Key offerings
Exhibit 71: Merck & Co. Inc. - Key customers
Exhibit 72: Novartis AG - Vendor overview
Exhibit 73: Novartis AG - Business segments
Exhibit 74: Novartis AG - Organizational developments
Exhibit 75: Novartis AG - Geographic focus
Exhibit 76: Novartis AG - Segment focus
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Novartis AG - Key customers
Exhibit 79: Sanofi - Vendor overview
Exhibit 80: Sanofi - Business segments
Exhibit 81: Sanofi - Organizational developments
Exhibit 82: Sanofi - Geographic focus
Exhibit 83: Sanofi - Segment focus
Exhibit 84: Sanofi - Key offerings
Exhibit 85: Sanofi - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors